Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment.
This article discusses the development of drugs and treatments in the context of issues of genetics, ethnicity, and culture. A brief overview of drug development, clinical trials methods, advertising and marketing practices, and the Alzheimer's Disease Cooperative Study (ADCS) recruitment program is followed by recommendations for enhancing diversity in the development of drugs for Alzheimer's disease.
Schneider
Lon S
LS
University of Southern California, Keck School of Medicine, Los Angeles, California, USA. lschneid@usc.edu
D000544:Alzheimer Disease / Q000188:drug therapy / Q000208:ethnology* / Q000235:genetics*; D002986:Clinical Trials as Topic; D018864:Cultural Diversity; D017277:Drug Approval / Q000458:organization & administration*; D006801:Humans; D008389:Marketing of Health Services / Q000458:organization & administration; D018579:Patient Selection; D014481:United States